Remove HIV Treatment and Prevention Agents Remove Packaging Remove Presentation
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This year Roche has secured the top position with a total R&D Expenditure of $15.20B, followed by Johnson & Johnson and AstraZeneca PharmaShots presents the Top 20 RNAi therapeutic companies based on their R&D Expenditure in the year 2022 R&D Expenditure: $43.1M R&D Expenditure: $85.1M R&D Expenditure: $437.9M

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Operational Flexibility/Capacity Decentralized manufacturing Presently, portable end-to-end CM plants are not a widespread reality, but have been proven possible.